South Korea
· Delayed Price · Currency is KRW Optipharm.CO.,LTD Statistics
Total Valuation
Optipharm.CO.,LTD has a market cap or net worth of KRW 78.34 billion. The enterprise value is 74.20 billion.
| Market Cap | 78.34B |
| Enterprise Value | 74.20B |
Important Dates
| Earnings Date | n/a |
| Ex-Dividend Date | n/a |
Share Statistics
Optipharm.CO.,LTD has 14.67 million shares outstanding. The number of shares has increased by 0.29% in one year.
| Shares Outstanding | 14.67M |
| Shares Change (YoY) | +0.29% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 6.88% |
| Owned by Institutions (%) | n/a |
| Float | 8.59M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 4.22 |
| PB Ratio | 3.29 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -30.25 |
| EV / Sales | 4.00 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -56.35 |
Financial Position
The company has a current ratio of 1.62, with a Debt / Equity ratio of 0.47.
| Current Ratio | 1.62 |
| Quick Ratio | 1.35 |
| Debt / Equity | 0.47 |
| Debt / EBITDA | n/a |
| Debt / FCF | -8.58 |
| Interest Coverage | -4.89 |
Financial Efficiency
Return on equity (ROE) is -9.58% and return on invested capital (ROIC) is -4.42%.
| Return on Equity (ROE) | -9.58% |
| Return on Assets (ROA) | -3.87% |
| Return on Capital (ROIC) | -4.42% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | 0.45 |
| Inventory Turnover | 10.34 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -28.80% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -28.80% |
| 50-Day Moving Average | 5,712.80 |
| 200-Day Moving Average | 6,425.90 |
| Relative Strength Index (RSI) | 37.65 |
| Average Volume (20 Days) | 10,810 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Optipharm.CO.,LTD had revenue of KRW 18.56 billion and -2.45 billion in losses. Loss per share was -167.23.
| Revenue | 18.56B |
| Gross Profit | 4.39B |
| Operating Income | -2.56B |
| Pretax Income | -2.45B |
| Net Income | -2.45B |
| EBITDA | -1.03B |
| EBIT | -2.56B |
| Loss Per Share | -167.23 |
Balance Sheet
The company has 15.43 billion in cash and 11.29 billion in debt, giving a net cash position of 4.14 billion or 282.06 per share.
| Cash & Cash Equivalents | 15.43B |
| Total Debt | 11.29B |
| Net Cash | 4.14B |
| Net Cash Per Share | 282.06 |
| Equity (Book Value) | 23.78B |
| Book Value Per Share | 1,620.88 |
| Working Capital | 8.12B |
Cash Flow
In the last 12 months, operating cash flow was -276.93 million and capital expenditures -1.04 billion, giving a free cash flow of -1.32 billion.
| Operating Cash Flow | -276.93M |
| Capital Expenditures | -1.04B |
| Free Cash Flow | -1.32B |
| FCF Per Share | -89.75 |
Margins
Gross margin is 23.64%, with operating and profit margins of -13.82% and -13.22%.
| Gross Margin | 23.64% |
| Operating Margin | -13.82% |
| Pretax Margin | -13.22% |
| Profit Margin | -13.22% |
| EBITDA Margin | -5.55% |
| EBIT Margin | -13.82% |
| FCF Margin | -7.09% |
Dividends & Yields
Optipharm.CO.,LTD does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -0.29% |
| Shareholder Yield | -0.29% |
| Earnings Yield | -3.13% |
| FCF Yield | -1.68% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Optipharm.CO.,LTD has an Altman Z-Score of 3.25.
| Altman Z-Score | 3.25 |
| Piotroski F-Score | n/a |